ARTICLE | Company News

Amersham International plc deal

July 10, 1995 7:00 AM UTC

Amersham's United States Biochemical Corp. subsidiary received an exclusive worldwide license from Harvard Medical School to a technology to develop DNA polymerases for use in DNA sequencing. Scientists at Harvard had previously developed Sequenase, a DNA sequencing enzyme. They now have used recombinant DNA technology to confer properties of Sequenase on other polymerases to create a series of new polymerases with enhanced properties for use in DNA sequence analysis (see Other Research News, page B7).

Amersham's Amersham Life Science group anticipates launching Thermo Sequenase through its direct sales force during this quarter. The product has the greatest application in fluorescent-based automated DNA sequencing, the company said. ...